NCT02285777View on ClinicalTrials.gov

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

March 26, 2015

Study Completion Date

June 11, 2015

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

Meningococcal ABCWY

One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)

BIOLOGICAL

Placebo

One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)

Trial Locations (8)

32934

GSK Investigational Site, Melbourne

35802

GSK Investigational Site, Huntsville

40207

GSK Investigational Site, Louisville

44121

GSK Investigational Site, Cleveland

67114

GSK Investigational Site, Newton

67207

GSK Investigational Site, Wichita

68134

GSK Investigational Site, Omaha

72401

GSK Investigational Site, Jonesboro

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02285777 - Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents | Biotech Hunter | Biotech Hunter